MedTrace Logo

Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation Following Functional Endoscopic Sinus Surgery

NCT07645521 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-06-12

No results posted yet for this study

Summary

This randomized double-blind controlled trial aims to evaluate whether bilateral trans-nasal sphenopalatine ganglion block (SPGB) using bupivacaine reduces the incidence of emergence agitation following Functional Endoscopic Sinus Surgery (FESS) compared with placebo. Secondary objectives include evaluation of postoperative pain, postoperative opioid consumption, hemodynamic parameters, postoperative nausea and vomiting, and adverse events.

Conditions

  • Chronic Rhinosinusitis (CRS)
  • Emergence Agitation

Interventions

PROCEDURE

Bilateral Trans-nasal Sphenopalatine Ganglion Block

Bilateral trans-nasal sphenopalatine ganglion block performed under direct endoscopic visualization using 1.5 mL of 0.5% bupivacaine per side.

PROCEDURE

Sham Trans-nasal Injection

Bilateral trans-nasal sham injection performed under direct endoscopic visualization using 1.5 mL of normal saline per side.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Amir Mostafa Shabana, MD · Faculty of Medicine, Mansoura University, Mansoura, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-05
Primary Completion
2026-02-07
Completion
2026-04-13

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07645521 on ClinicalTrials.gov